The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 30, 2012

Filed:

Mar. 13, 2009
Applicants:

Scott Peter Webster, Edinburgh, GB;

Jonathan Robert Seckl, Edinburgh, GB;

Brian Robert Walker, Edinburgh, GB;

Peter Ward, Middlesex, GB;

Thomas David Pallin, Harlow, GB;

Hazel Joan Dyke, Harlow, GB;

Trevor Robert Perrior, Bury St Edmunds, GB;

Inventors:

Scott Peter Webster, Edinburgh, GB;

Jonathan Robert Seckl, Edinburgh, GB;

Brian Robert Walker, Edinburgh, GB;

Peter Ward, Middlesex, GB;

Thomas David Pallin, Harlow, GB;

Hazel Joan Dyke, Harlow, GB;

Trevor Robert Perrior, Bury St Edmunds, GB;

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/55 (2006.01); A61K 31/551 (2006.01); A61K 31/541 (2006.01); A61K 31/5355 (2006.01); A61K 31/536 (2006.01); A61K 31/496 (2006.01); A61K 31/498 (2006.01); A61K 31/4709 (2006.01); A61K 31/451 (2006.01); A61K 31/4535 (2006.01); A61K 31/4402 (2006.01); A61K 31/4155 (2006.01); C07D 243/08 (2006.01); C07D 401/14 (2006.01); C07D 403/14 (2006.01); C07D 265/36 (2006.01); C07D 265/30 (2006.01); C07D 279/12 (2006.01); C07D 231/12 (2006.01); C07D 239/04 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.


Find Patent Forward Citations

Loading…